Fourty eight hours treatment in vitro with therapeutic doses of JNJ-605, a small-molecule tyrosine kinase inhibitor (TKi) highly selective for MET,49,50 significantly impaired the upregulation of PD-L1 at the cell membrane induced by IFNγ, in all MET-amplified cancer cell lines included in our panel. This evidence concerns the gene IFNG and cancer.